DHR vs RGEN: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of September 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: DHR is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. DHR and RGEN share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined DHR and RGEN exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Danaher Corporation is a global science and technology company built around three segments: Biotechnology (bioprocessing tools and consumables used to make biologic drugs, led by Cytiva and Pall), Life Sciences (instruments and reagents for research, including brands like Beckman Coulter Life Sciences, SCIEX, and Leica Microsystems), and Diagnostics (clinical and molecular testing through Beckman Coulter Diagnostics, Radiometer, Leica Biosystems, and Cepheid). A large share of revenue is recurring consumables and service tied to installed instruments and ongoing drug manufacturing, which is the core of the investment appeal. Danaher runs the well-known Danaher Business System, a continuous-improvement operating model it uses to drive margins and integrate acquisitions.

Full DHR guide

Repligen Corporation makes consumable products and equipment used to manufacture biologic drugs, including monoclonal antibodies, gene therapies and vaccines. Its portfolio spans four franchises: filtration (KrosFlo and XCell ATF systems), chromatography resins and columns, proteins (notably Protein A ligands used to purify antibodies), and process analytics. Because roughly 80% of its offerings face limited direct competition and its consumables are embedded in customers' validated manufacturing processes, Repligen sells into a durable, recurring bioprocessing demand base rather than one-off equipment cycles.

Full RGEN guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• DHR drivers: Bioprocessing recovery; Recurring consumables and razor-and-blade mix.
• RGEN drivers: Bioprocessing recovery and organic reacceleration; New modalities and consumables mix.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Valuation is the most cited risk, since DHR often trades at a premium multiple (trailing P/E has ranged roughly from the mid-30s to mid-40s), leaving little room for disappointment. For RGEN, repligen trades at a rich valuation (around 8 times sales), so any stumble in organic growth or guidance can trigger sharp multiple compression.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick DHR if you believe its drivers more; RGEN if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the DHR and RGEN guides.

DHR. Danaher grew 2025 revenue about 2.9% to ~$24.6B with ~2% core growth, while adjusted EPS grew faster on margins and buybacks. The stock has typically carried a premium valuation, with a trailing P/E in the mid-30s to mid-40s and a forward P/E closer to the low 20s as estimates rise. Figures are approximate and as of JULY 2026.

RGEN. Repligen carries a premium valuation typical of high-quality life-science tools names, with a price-to-sales ratio near 8 despite mid-teens headline revenue growth. Management raised its 2026 profit outlook while roughly holding revenue guidance, reflecting a recovery that is more visible in margins than in top-line acceleration so far. The shares are widely viewed as fully priced on sales even if cash flow looks more reasonable.

Headline figures (approximate, JULY 2026): DHR shows revenue (fy2025) ~$24.6B, adj. diluted eps (fy2025) ~$7.80, free cash flow (fy2025) ~$5.3B, 2026 adj. eps guidance ~$8.35 to $8.55; RGEN shows revenue (ttm) ~$708M, fy2026 revenue guidance ~$810M to $840M, q1 2026 revenue growth ~15% reported (11% organic), fy2026 adjusted eps guidance ~$1.97 to $2.05.

DHR and RGEN are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined DHR and RGEN exposure against your real portfolio. It is not an investment adviser.